neuromuscular disorder

  • Breakthrough: Atossa’s (Z)-Endoxifen Gains FDA Orphan Status for DMD

    Breakthrough: Atossa’s (Z)-Endoxifen Gains FDA Orphan Status for DMD

    Atossa Therapeutics (Nasdaq: ATOS) said the FDA granted Orphan Drug Designation for its drug (Z)-endoxifen in Duchenne muscular dystrophy. This follows a prior Rare Pediatric Disease designation. It’s a positive regulatory step. But it does not guarantee approval and it does not make trials any faster. CEO Steven Quay called it an important milestone. He…

    read more